NUMD · XBRL financial data
Nu-Med Plus financial statements, every fiscal year
The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (NUMD's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | — | — | — | — | — |
| General and administrative | 58 | 32 | 27 | 28 | 34 | 23 |
| Total operating expenses | 1,995 | 839 | 182 | 121 | 63 | 49 |
| Operating income (loss) | (1,995) | (839) | (182) | (121) | (63) | (49) |
| Interest income | 0 | — | — | — | — | — |
| Interest expense | 14 | — | 1 | 5 | 5 | 7 |
| Income tax expense (benefit) | 0 | — | — | — | — | — |
| Net income (loss) | (2,009) | (830) | (130) | (126) | (68) | (56) |
| Earnings per share, basic USD per share | (0.04) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | (0.04) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted average shares, basic thousands of shares | 54,515 | 73,374 | 79,951 | 81,674 | 83,548 | 83,548 |
| Weighted average shares, diluted thousands of shares | 54,515 | 73,374 | 79,951 | 81,674 | 83,548 | 83,548 |
Balance sheet
CSVFiscal years (NUMD's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 189 | 12 | 73 | 7 | 2 | 1 |
| Total current assets | 538 | 12 | 80 | 13 | 9 | 8 |
| Property and equipment, net | 12 | 2 | — | — | — | 0 |
| Right-of-use asset | 8 | 8 | — | — | — | — |
| Total assets | 557 | 22 | 80 | 13 | 9 | 8 |
| Accounts payable | 26 | 28 | 7 | 8 | 43 | 48 |
| Accrued liabilities | 26 | 93 | 1 | 6 | 15 | 18 |
| Total current liabilities | 80 | 155 | 143 | 160 | 224 | 279 |
| Long-term debt | — | — | — | — | — | 0 |
| Total liabilities | 89 | 155 | 143 | 160 | 224 | 279 |
| Accumulated deficit | (8,739) | (9,569) | (9,699) | (9,825) | (9,893) | (9,950) |
| Total stockholders' equity | 468 | (132) | (63) | (147) | (215) | (271) |
| Total liabilities and equity | 557 | 22 | 80 | 13 | 9 | 8 |
| Common shares outstanding (cover page) thousands of shares | 79,348 | 79,348 | 81,348 | 83,548 | 83,548 | 83,548 |
Cash flows
CSVFiscal years (NUMD's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (2,009) | (830) | (130) | (126) | (68) | (56) |
| Stock-based compensation | 961 | 200 | 35 | 42 | — | — |
| Net cash from operating activities | (415) | (207) | (38) | (66) | (4) | (48) |
| Net cash from investing activities | 0 | — | — | — | — | — |
| Proceeds from issuing common stock | 200 | 30 | — | — | — | — |
| Proceeds from issuing equity | 0 | — | — | — | — | — |
| Net cash from financing activities | 596 | 30 | 100 | — | — | 46 |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Nu-Med Plus | 5.4 | 0 | 1.1* | 83.5M | — | 10-QJun 30, 2026 |
| STRATA Skin Sciences | 7,912 | 9,292* | (239)* | 5.9M | 33.1 quarters | 10-KDec 31, 2025 |
| ENDRA Life Sciences | 1,740 | not reported | (928)* | 1.5M | 1.9 quarters | 10-QJun 30, 2026 |
| Catheter Precision | 643 | 1,019 | (2,861)* | 14.4M | 0.6 quarters | 10-QJun 30, 2026 |
| Global Innovative Platforms | 244 | 51 | (134)* | 49.8M | 1.8 quarters | 10-QJun 30, 2026 |
| Interpace Biosciences | 2,688 | 9,131 | 98* | 27.7M | — | 10-QJun 30, 2026 |
| Bluejay Diagnostics | 9,599 | not reported | (1,499)* | 4.5M | 6.4 quarters | 10-QJun 30, 2026 |
| Stimcell Energetics | 6.9 | not reported | (109) | 21.1M | 0.1 quarters | 10-QAug 31, 2026 |
| LogicMark | 3,496 | 3,349 | 83* | 899,759 | — | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.